Human body cells are stem cell (SC) derivatives originating from bone marrow. Their special
characteristics include their capacity to support the formation and self-repair of the cells …

目的: 对行静脉大剂量美法仑联合外周血自体造血干细胞移植治疗多发性骨髓瘤(
multiplemyeloma, MM) 患者的无进展生存期(progression-freesurvival, PFS) …

Multiple myeloma (MM) stands as the second most prevalent hematological malignancy,
constituting approximately 10% of all hematological malignancies. Current guidelines …

Simple Summary Refractoriness to the five main myeloma treatments, including
lenalidomide, pomalidomide, bortezomib, carfilzomib, and either daratumumab or …

Advances in treatment have improved the survival of multiple myeloma (MM) patients, but
the disease remains incurable. Here, in this nationwide retrospective real-world evidence …

目的: 探究海曲泊帕治疗慢性原发免疫性血小板减少症(primaryimmunethrombocytopenia, ITP)
的临床疗效和安全性. 方法: 选取2021 年6 月—2022 年12 月我院血液内科收治的25 例慢性ITP …

OBJECTIVES: ASCT has been considered the standard of care for younger patients with
NDMM, however, not all the studies published so far have uniformly demonstrated the …

Next Generation Flow (NGF) represents a gold standard for the evaluation of Minimal
Residual Disease (MRD) in Multiple Myeloma (MM) patients at any stage of treatment …

Over the last 10 to 20 years, there have been significant improvements in the fields of both
autologous and allogenic transplantation. The upper age limit for hematopoietic stem cell …

Multiple myeloma (MM) is a hematologic cancer defined by an abnormal development of
clonal plasma cells in the bone marrow, releasing vast quantities of immunoglobulins and …